Revolution shows its selective hand
The company will start three phase 3 trials of its G12D project this year.
Revolution goes adjuvant
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
HengRui goes pivotal in KRAS G12D
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
Triple meeting 2025 – Revolution hints at post-KRAS promise
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
ESMO 2025 – Incyte impresses in KRAS G12D
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
Merck shoots for KRAS all comers
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
Revolution could have a first-line pancreatic balancing act
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
